Parenteral drug delivery; DNA origami builds a drug-delivery monorail;

> Pharma magazine takes in in-depth look at the commercialization of parenteral drug delivery systems based on microspheres, nanotechnology and implants. Article

> Inovio Pharmaceuticals unveils needle-free, contactless electroporation technology for DNA vaccine delivery Inovio release

> Lacerta Bio has a new client: A nanoparticle-based formulation and drug delivery company. More here

> Greystone Research Associates says needle-free injection (NFI) is attempting to shed its image as an out-of-the-mainstream drug delivery technique. The convergence of improved device designs, patient sentiment and new therapeutic applications is remaking NFI into an attractive technology being pursued by a number of major pharmaceutical companies. Release

> DNA origami builds a drug-delivery monorail. Yes, really. Read it

Suggested Articles

Purdue's reformulated OxyContin may stop patients from snorting or injecting the drug, but it doesn't curb abuse overall, an FDA panel determined.

Roche is gearing up to launch an eye implant to make its Lucentis AMD drug easier to use. But the drugmaker has even bigger plans for the device.

Delivery specialist IntelGenx struck two deals to develop oral films for prescription psychedelics this summer with Canada's Cybin and ATAI.